XClose

UCL Campaign

Home
Menu

Alpha-1 Awareness UK make £25,000 donation to Alpha-1 Antitrypsin Deficiency research at UCL

5 February 2018

Alan and Emma Wooler, Chairperson and trustee of Alpha-1 Awareness UK, visited UCL on 20th January with their family to meet Professor David Lomas and present a cheque for £25,000 to support the research of a cure for Alpha-1 Antitrypsin Deficiency (AATD).

Trustees daughter hands over the cheque to Prof Lomas

Alpha-1 Awareness UK were the first support group to be registered in the UK and are working to improve understanding of AATD, to raise awareness of the condition and provide support for those who have been diagnosed, their carers and their families. The donation made by the Alpha-1 Awareness UK is the largest donation they have ever made and as their Chairperson Alan Wooler notes, it is a big step for the charity.

“Our supporters have been working hard to raise money for Alpha-1 Antitrypsin Deficiency research; we have seen fundraisers complete half marathons, marathons, sky dives and obstacle courses to name but a few! We are incredibly grateful to them and very proud to make this donation to -Professor Lomas and his team. All of us at Alpha-1 Awareness UK have been impacted directly and in-directly by this condition so it is particularly special to be able to present this cheque to Professor Lomas.”

Alan Wooler shakes the hand of Prof Lomas

AATD is a relatively common genetic condition, and one of the most common inherited disorders affecting one in 2,000 people. Despite this, it often goes undiagnosed. Patients with AATD are predisposed to obstructive pulmonary disease and liver disease.

Professor David Lomas, Vice-Provost Health at UCL and Patron of Alpha-1 Awareness UK, has worked on the pathobiology of AATD for over 25 years. His research team at UCL described the molecular basis of AATD and are working closely with GlaxoSmithKline to develop effective treatments and cures.

As Professor Lomas describes, finding effective treatments or a cure for those affected by AATD would make an immense difference to patients and their families.

“Currently, the only option for patients with liver disease as a result of AATD is transplantation. The support of organisations such as Alpha-1 Awareness UK enables us to continue to make great strides forwards in terms of finding cutting edge treatments that will make a real and tangible difference to those who are affected. We are incredibly grateful to Alan and all those at Alpha-1 Awareness UK who continue to support our research.”

Find out more about Alpha-1 Awareness UK: http://www.alpha1.uk/